For patients with early breast cancer knowledge of germline BRCA1/2 status increasingly influences management as well as informing future cancer risk for patients and their families. Newly diagnosed patients are now benefiting from expanded access to testing. To extend this provision to breast cancer survivors, we embedded a Senior Genetic Counsellor in the Breast Unit Open Access Follow Up programme to identify patients suitable for genetics review 5 years after their breast cancer diagnosis. This collaboration resulted in the identification of further carriers and strengthened the multidisciplinary working of the two teams. (By Dr Zoe Kemp, https://jmg.bmj.com/content/early/2019/09/10/jmedgenet-2019-106420 )